Helus Pharma Reports Positive Phase 2 Results for HLP004 in Generalized Anxiety Disorder Treatment

Helus Pharma reported topline results from a Phase 2 signal detection study evaluating HLP004 as a potential adjunctive treatment for adults with moderate-to-severe generalized anxiety disorder who remained symptomatic despite ongoing standard-of-care antidepressant therapy. Patients receiving 20 mg HLP004 alongside standard treatments achieved a mean 10.4-point reduction in HAM-A anxiety scores at six weeks, with the study demonstrating durable response rates, favorable tolerability and a short in-clinic treatment experience, supporting continued development of the therapy for a patient population with limited treatment options.

The company's proprietary novel serotonergic agonists are synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity. These NSAs are intended to address the large unmet need for people who suffer from depression, anxiety, and other mental health conditions. With class leading data, Helus Pharma aims to improve the treatment landscape through the introduction of NSAs that aim to provide durable improvements in mental health.

Helus Pharma is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of major depressive disorder that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. The company also has HLP004 in Phase 2 for generalized anxiety disorder and maintains an extensive research portfolio of investigational NSAs. The positive Phase 2 results for HLP004 represent a significant step forward in addressing the treatment gap for patients with generalized anxiety disorder who do not respond adequately to current therapies.

The company operates in Canada, the United States, the United Kingdom and Ireland. For more information about Helus Pharma's developments, visit https://www.helus.com. The full press release detailing these Phase 2 results can be accessed at https://ibn.fm/mnw3T. These findings come at a critical time when mental health treatment options remain limited for many patients, particularly those who experience inadequate response to existing antidepressant therapies.

The study's statistical significance, demonstrated by the p<0.0001 result, underscores the potential clinical relevance of HLP004 for patients struggling with generalized anxiety disorder. The durable response rates observed in the trial suggest that HLP004 may offer sustained benefits beyond immediate symptom relief, which represents an important advancement in anxiety treatment approaches. The favorable tolerability profile noted in the study could address common concerns about side effects that often limit treatment adherence in anxiety disorders.

As mental health conditions continue to represent a significant global health burden, the development of novel treatment approaches like HLP004 takes on increased importance. The Phase 2 results provide a foundation for further clinical investigation and potential regulatory submissions, moving the therapy closer to becoming available for patients who currently have few effective options. The company's focus on neuroplasticity through serotonergic pathway activation represents a distinct approach to mental health treatment that differs from conventional pharmacological strategies.